Class Action Deadline Adds Legal Overhang to Aquestive's Anaphylm Binary

What happened

Faruqi & Faruqi, LLP has filed a securities class action against Aquestive Therapeutics, reminding investors of the May 4, 2026 lead plaintiff deadline for claims related to alleged misrepresentations between June 16, 2025 and January 8, 2026. This legal development compounds the already-binary regulatory and commercial risk around Anaphylm, which we have long flagged as overpriced given its encumbered balance sheet and competitive pressure from neffy. Our DeepValue analysis rates AQST as a POTENTIAL SELL with a base case value of $7.00 and a bear case of $3.50, reflecting the narrow margin of safety and unfavorable payoff skew. The class action introduces additional downside risk and legal costs, potentially distracting management and accelerating capital needs. At the current price, sentiment remains bullish despite widening losses and a stockholders' deficit, making the risk/reward unattractive.

Implication

The securities class action adds a new layer of downside risk, potentially diverting management attention and increasing legal expenses. Combined with our earlier thesis on Anaphylm's binary approval, intense payer discounting, and a leveraged balance sheet, the stock's risk/reward remains skewed to the downside. Even if Anaphylm is approved, commercialization challenges and royalty obligations limit upside to our base case of $7.00. Investors should not ignore the class action as noise – it signals potential disclosure deficiencies that could undermine credibility. At $6.21, the market is pricing in a best-case scenario that ignores both the litigation and the company's financial fragility.

Thesis delta

The new class action introduces legal risk that was not fully captured in our original thesis. While we already viewed AQST as overvalued due to Anaphylm's binary outcome and balance sheet constraints, the lawsuit adds potential liability, reputation damage, and distraction. This shifts the already unfavorable payoff skew further toward the downside, making the stock even less attractive near current levels. The thesis remains a POTENTIAL SELL, but with increased conviction as legal overhang compounds the existing risks.